| 苏梦茹,范晓雁,谢海蓉,郑鑫雨,孙杏红.糖尿病黄斑水肿患者行雷珠单抗治疗前后OCT参数、实验室血清指标的表达差异变化及预后影响因素分析[J].,2024,(21):4082-4085 |
| 糖尿病黄斑水肿患者行雷珠单抗治疗前后OCT参数、实验室血清指标的表达差异变化及预后影响因素分析 |
| Analysis of the Differential Expression of OCT Parameters and Laboratory Serum Indicators and Prognostic Factors in Patients with Diabetic Macular Edema before and after Treatment with Ranibizumab |
| 投稿时间：2024-05-16 修订日期：2024-06-12 |
| DOI：10.13241/j.cnki.pmb.2024.21.014 |
| 中文关键词: 黄斑水肿 光学相干断层扫描 血管内皮生长因子 |
| 英文关键词: Macular edema Optical coherence tomography Vascular endothelial growth factor |
| 基金项目:江苏省中医药科技发展计划面上项目（MS2022078） |
|
| 摘要点击次数: 40 |
| 全文下载次数: 14 |
| 中文摘要: |
| 摘要 目的：探讨DME患者行雷珠单抗治疗前后OCT参数、实验室血清指标的表达差异变化及预后影响因素。方法：回顾性分析2022.4-2023.11月收治的92例（130眼）DME患者，对比患者的各项指标。治疗4个月后根据黄斑区中央视网膜厚度将患者分为预后良好组70例（90眼）和预后不良组22例（40眼），分析DME患者行雷珠单抗治疗的预后影响因素。结果：治疗后4个月患者SND高度、CST均降低（P＜0.05）；治疗后1个月IL-8、VEGF、IL-6水平均降低，PEDF升高（P＜0.05）；预后组患者年龄、病变分级、病情分类、SND高度、CST、VEGF、IL-6表达水平对比差异显著（P＜0.05）；病变分级、CST、VEGF、IL-6为DME患者行雷珠单抗治疗的预后独立危险因素（P＜0.05）。结论：玻璃体腔注射雷珠单抗治疗DME可改善其OCT参数，降低血清IL-8、VEGF、IL-6水平，提高PEDF水平。黄斑水肿分期、CST、VEGF及IL-6水平可对早期患者预后水平预测提供重要参考。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the differential expression of optical coherence tomography (OCT) parameters, laboratory serum indicators and prognostic factors in patients with diabetic macular edema (DME) before and after treatment with Ranibizumab. Methods: Retrospective analysis of 92 DME patients (130 eyes) admitted from April 2022 to November 2023, comparing various indicators of the patients. After 4 months of treatment, patients were divided into a good prognosis group of 70 cases (90 eyes) and a poor prognosis group of 22 cases (40 eyes) based on the thickness of the central retina in the macular area. The prognostic factors of DME patients treated with ranibizumab were analyzed. Results: After 4 months of treatment, the SND height and CST of the patient decreased (P<0.05); After one month of treatment, the average levels of IL-8, VEGF, and IL-6 decreased, while PEDF increased(P<0.05); There were significant differences(P<0.05) in age, lesion grading, disease classification, SND height, CST, VEGF, and IL-6 expression levels among patients in the prognostic group; Disease grading, CST, VEGF, and IL-6 are independent prognostic risk factors for DME patients treated with ranibizumab(P<0.05). Conclusion: Ranibizumab treatment of DME can improve its OCT parameters, reduce serum levels of IL-8, VEGF, IL-6, and increase the level of PEDF. However, observation of macular edema stage, CST, VEGF, and IL-6 levels before treatment can provide an important reference for predicting the prognosis of early patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
